An armed oncolytic virus for GBM destruction

被引：0

作者：

Judit Sanchez Gil

Samuel D. Rabkin

机构：

[1] Massachusetts General Hospital and Harvard Medical School,Brain Tumor Research Center, Department of Neurosurgery

来源：

Nature Cancer | 2022年 / 3卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Immunovirotherapy is a promising therapeutic strategy for glioblastoma (GBM), a deadly tumor for which effective treatments remain a clinical need. A new study describes an oncolytic herpes simplex virus (oHSV) armed with a bispecific anti-EGFR–CCL5 fusion protein that activates innate and adaptive antitumor immune responses that are highly efficacious in preclinical GBM models.

引用

页码：1274 / 1276

页数：2

共 17 条

[1]

Burster T(2021)undefined Front. Cell Dev. Biol. 9 695325-53

[2]

Himes BT(2021)undefined Front. Oncol. 11 770561-1622

[3]

Medikonda R(2021)undefined J. Neurooncol. 151 41-1639

[4]

Yeo ECF(2021)undefined Cells 10 607-6171

[5]

Cai WQ(2020)undefined Front. Oncol. 10 1249-406

[6]

Tian L(2022)undefined Nat. Cancer 13 1740-undefined

[7]

Jahan N(2021)undefined Viruses 384 1613-undefined

[8]

Friedman GK(2021)undefined N. Engl. J. Med. 28 1630-undefined

[9]

Todo T(2022)undefined Nat. Med. 38 6159-undefined

[10]

Totsch SK(2019)undefined Oncogene 41 35-undefined

← 1 2 →